Literature DB >> 26667490

Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.

Aaron S Mansfield1, Stephen J Murphy2, Tobias Peikert3, Eunhee S Yi4, George Vasmatzis2, Dennis A Wigle5, Marie Christine Aubry4.   

Abstract

PURPOSE: The expression of programmed cell death ligand 1 (PD-L1) provides limited predictive value in identifying patients most likely to respond to immunotherapy. As the heterogeneity of PD-L1 expression may lead to sampling error and the misclassification of PD-L1 status, we assessed the distribution of PD-L1 expression in paired, resected multifocal lung cancers. EXPERIMENTAL
DESIGN: PD-L1 was assessed by IHC. Paired lesions were defined as independent primaries or related lesions using mate pair next-generation sequencing. Agreement statistics were used for analysis.
RESULTS: Sixty-seven multifocal lung cancers from 32 patients were sequenced and stained for PD-L1. There was agreement of PD-L1 expression by the tumor cells in paired lesions of 20 patients and disagreement of PD-L1 expression by the tumor cells in paired lesions of 12 patients (κ = 0.01). Sequencing identified that 23 patients had independent primary lung cancers and that 9 patients had related cancers. In paired lesions of patients with independent cancers, there was agreement of PD-L1 expression by the tumor cells in 12 patients and disagreement in 11 patients (κ = 0.31). In paired lesions of patients with related lung cancers, there was agreement of PD-L1 expression by the tumor cells in 8 patients and disagreement in 1 patient (κ = 0.73).
CONCLUSIONS: The expression of PD-L1 is heterogeneous among paired independent lung cancers, but there are high levels of agreement in intrapulmonary metastasis. Clin Cancer Res; 22(9); 2177-82. ©2015 AACR. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26667490      PMCID: PMC4854782          DOI: 10.1158/1078-0432.CCR-15-2246

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

2.  Circos: an information aesthetic for comparative genomics.

Authors:  Martin Krzywinski; Jacqueline Schein; Inanç Birol; Joseph Connors; Randy Gascoyne; Doug Horsman; Steven J Jones; Marco A Marra
Journal:  Genome Res       Date:  2009-06-18       Impact factor: 9.043

3.  Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer.

Authors:  Stephen J Murphy; Marie-Christine Aubry; Faye R Harris; Geoffrey C Halling; Sarah H Johnson; Simone Terra; Travis M Drucker; Michael K Asiedu; Benjamin R Kipp; Eunhee S Yi; Tobias Peikert; Ping Yang; George Vasmatzis; Dennis A Wigle
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.

Authors:  Nicolas Girard; Charuhas Deshpande; Christopher Lau; David Finley; Valerie Rusch; William Pao; William D Travis
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

Review 7.  Surgical treatments for multiple primary adenocarcinoma of the lung.

Authors:  Masao Nakata; Shigeki Sawada; Motohiro Yamashita; Hideyuki Saeki; Akira Kurita; Shigemitsu Takashima; Kazuo Tanemoto
Journal:  Ann Thorac Surg       Date:  2004-10       Impact factor: 4.330

8.  Multiple primary lung cancers. Results of surgical treatment.

Authors:  C Deschamps; P C Pairolero; V F Trastek; W S Payne
Journal:  J Thorac Cardiovasc Surg       Date:  1990-05       Impact factor: 5.209

9.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

Authors:  George Vasmatzis; Sarah H Johnson; Ryan A Knudson; Rhett P Ketterling; Esteban Braggio; Rafael Fonseca; David S Viswanatha; Mark E Law; N Sertac Kip; Nazan Ozsan; Stefan K Grebe; Lori A Frederick; Bruce W Eckloff; E Aubrey Thompson; Marshall E Kadin; Dragana Milosevic; Julie C Porcher; Yan W Asmann; David I Smith; Irina V Kovtun; Stephen M Ansell; Ahmet Dogan; Andrew L Feldman
Journal:  Blood       Date:  2012-08-01       Impact factor: 22.113

10.  Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.

Authors:  Stephen J Murphy; John C Cheville; Shabnam Zarei; Sarah H Johnson; Robert A Sikkink; Farhad Kosari; Andrew L Feldman; Bruce W Eckloff; R Jeffrey Karnes; George Vasmatzis
Journal:  DNA Res       Date:  2012-09-18       Impact factor: 4.458

View more
  46 in total

Review 1.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

Review 2.  The current state of molecular testing in the treatment of patients with solid tumors, 2019.

Authors:  Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall
Journal:  CA Cancer J Clin       Date:  2019-05-22       Impact factor: 508.702

3.  Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.

Authors:  Simone B S P Terra; Aaron S Mansfield; Haidong Dong; Tobias Peikert; Anja C Roden
Journal:  Oncoimmunology       Date:  2017-07-27       Impact factor: 8.110

Review 4.  Immune checkpoint inhibitors in small cell lung cancer.

Authors:  Suchita Pakkala; Taofeek K Owonikoko
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

5.  Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Authors:  Aaron S Mansfield; Tobias Peikert; James B Smadbeck; Julia B M Udell; Enrique Garcia-Rivera; Laura Elsbernd; Courtney L Erskine; Virginia P Van Keulen; Farhad Kosari; Stephen J Murphy; Hongzheng Ren; Vishnu V Serla; Janet L Schaefer Klein; Giannoula Karagouga; Faye R Harris; Carlos Sosa; Sarah H Johnson; Wendy Nevala; Svetomir N Markovic; Aaron O Bungum; Eric S Edell; Haidong Dong; John C Cheville; Marie Christine Aubry; Jin Jen; George Vasmatzis
Journal:  J Thorac Oncol       Date:  2018-10-10       Impact factor: 15.609

6.  Management of Multifocal Lung Cancer: Results of a Survey.

Authors:  Konstantinos Leventakos; Tobias Peikert; David E Midthun; Julian R Molina; Shanda Blackmon; Francis C Nichols; Yolanda I Garces; Christopher L Hallemeier; Stephen J Murphy; George Vasmatzis; Sarah L Kratz; William P Holland; Charles F Thomas; John J Mullon; K Robert Shen; Stephen D Cassivi; Randolph S Marks; Marie Christine Aubry; Alex A Adjei; Ping Yang; Mark S Allen; Eric S Edell; Dennis Wigle; Aaron S Mansfield
Journal:  J Thorac Oncol       Date:  2017-06-03       Impact factor: 15.609

7.  In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.

Authors:  Daniel J Rubins; Xiangjun Meng; Paul McQuade; Michael Klimas; Krista Getty; Shu-An Lin; Brett M Connolly; Stacey S O'Malley; Hyking Haley; Mona Purcell; Liza Gantert; Marie Holahan; Joel Lindgren; Pär Eklund; Caroline Ekblad; Fredrik Y Frejd; Eric D Hostetler; Dinko E González Trotter; Jeffrey L Evelhoch
Journal:  Mol Imaging Biol       Date:  2020-10-23       Impact factor: 3.488

8.  T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

Authors:  Roxana S Dronca; Xin Liu; Susan M Harrington; Lingling Chen; Siyu Cao; Lisa A Kottschade; Robert R McWilliams; Matthew S Block; Wendy K Nevala; Michael A Thompson; Aaron S Mansfield; Sean S Park; Svetomir N Markovic; Haidong Dong
Journal:  JCI Insight       Date:  2016-05-05

Review 9.  Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.

Authors:  Xiaolei Li; Wenhui Song; Changshun Shao; Yufang Shi; Weidong Han
Journal:  Cell Mol Immunol       Date:  2018-07-12       Impact factor: 11.530

10.  The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.

Authors:  Rui Kitadai; Yusuke Okuma; Taiki Hakozaki; Yukio Hosomi
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.